10-K · June 29, 2026
Elite Pharmaceuticals demonstrated a significantly positive performance in FY 2026, with revenues increasing by 77% to $148.9 million over the previous year, driven by new product launches and a surge in manufacturing…
Earnings analysis · 10-Q
ELTP earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
Elite reported $40.748 million of revenue and $0.01 of EPS, but the provided filing excerpt does not disclose margin, cash-flow, balance-sheet, or segment trends. The most material disclosure is management’s conclusion…
Read full summary
Elite reported $40.748 million of revenue and $0.01 of EPS, but the provided filing excerpt does not disclose margin, cash-flow, balance-sheet, or segment trends. The most material disclosure is management’s conclusion that disclosure controls and internal control over financial reporting were ineffective as of June 30, 2026, due to 3 categories of material weaknesses. The Purdue Pharma litigation was dismissed on June 12, 2026, but generic OxyContin commercialization remains contingent on FDA approval and patent outcomes. No quantitative guidance was provided, and the filing states that risk factors had no material changes from the March 31, 2026 Form 10-K.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.01
What stood out
-
Revenue and EPS reported
Reported revenue was $40.748 million and EPS was $0.01 for the period. The filing excerpt does not provide comparable prior-period or prior-year revenue, margin, or EPS figures.
-
OxyContin litigation dismissed
The company dismissed the Purdue Pharma patent-infringement case on June 12, 2026, after the parties agreed to a stipulated dismissal.
-
OxyContin launch remains conditional
Elite stated that launch of generic OxyContin depends on FDA approval and the outcome of litigation or expiration of patents listed in the Orange Book.
-
Material control weaknesses identified
Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, citing 3 categories of material control deficiencies.
-
Remediation efforts underway
The company began remediation during the 3 months ended June 30, 2026, focusing on control documentation and oversight of manufacturing, marketing, distribution, and reporting activities.
What to watch
-
Material weakness in financial controls
Management concluded that internal control over financial reporting was not effective as of June 30, 2026. The filing cites insufficient segregation of duties, limited personnel and resources, and weaknesses in control activities and documentation, creating a reasonable possibility that a misstatement may not be prevented or detected timely.
-
Remediation timing remains uncertain
The company stated that the material weaknesses cannot be considered remediated until remedial controls operate for a sufficient period and management completes testing of their design and operating effectiveness. No remediation completion date was provided.
-
FDA and patent approval uncertainty
Although the Purdue Pharma case was dismissed on June 12, 2026, Elite’s generic OxyContin launch still depends on FDA approval and patent-related outcomes, leaving commercialization timing uncertain.
Management's outlook
The 10-Q does not provide quantitative revenue or EPS guidance, nor does it state that prior guidance was raised, maintained, lowered, or withdrawn.
Earlier filings 4
10-Q · February 17, 2026
Elite Pharmaceuticals reported robust growth in Q3 fiscal 2026, achieving revenues of $31.6 million, a 120% increase year-over-year, though this fell short of consensus estimates. The company recorded an EPS of $0.01,…
10-Q · November 14, 2025
Elite Pharmaceuticals, Inc. reported robust growth in Q2 of fiscal 2025, with revenue reaching $36.3 million, a 92% increase compared to $18.9 million in Q2 of fiscal 2024. EPS was reported at $0.01, showing a…
10-Q · August 14, 2025
Elite Pharmaceuticals, Inc. reported Q4 fiscal year 2025 results showing significant growth, with revenues of $40.21 million, up 114% from the previous year, driven by an increase in manufacturing fees. The company…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.